Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS.

Nofech-Mozes S, Hanna W, Rakovitch E.

Am J Pathol. 2019 May;189(5):975-980. doi: 10.1016/j.ajpath.2018.12.003. Epub 2018 Dec 31. Review.

PMID:
30605628
2.
3.

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score.

Lalani N, Rakovitch E.

Cureus. 2017 Apr 21;9(4):e1185. doi: 10.7759/cureus.1185.

4.

Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ.

Raldow AC, Sher D, Chen AB, Recht A, Punglia RS.

J Clin Oncol. 2016 Nov 20;34(33):3963-3968. doi: 10.1200/JCO.2016.67.8532. Epub 2016 Sep 30.

PMID:
27621393
5.

Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.

Lin CY, Mooney K, Choy W, Yang SR, Barry-Holson K, Horst K, Wapnir I, Allison K.

Mod Pathol. 2018 Apr;31(4):562-568. doi: 10.1038/modpathol.2017.172. Epub 2017 Dec 15.

6.

The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.

Alvarado M, Carter DL, Guenther JM, Hagans J, Lei RY, Leonard CE, Manders J, Sing AP, Broder MS, Cherepanov D, Chang E, Eagan M, Hsiao W, Schultz MJ.

J Surg Oncol. 2015 Jun;111(8):935-40. doi: 10.1002/jso.23933. Epub 2015 May 28.

PMID:
26031501
7.

Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score.

Woodard GA, Price ER.

AJR Am J Roentgenol. 2019 Apr;212(4):919-924. doi: 10.2214/AJR.18.20306. Epub 2019 Feb 4.

PMID:
30714832
8.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby A, Thomas JSJ, Maxwell AJ, Wallis MG, Dodwell DJ; Sloane Project Steering Group (NHS Prospective Study of Screen-Detected Non-invasive Neoplasias).

Eur J Cancer. 2018 Sep;101:210-219. doi: 10.1016/j.ejca.2018.06.027. Epub 2018 Aug 6.

PMID:
30092498
9.

Selective use of whole breast radiotherapy after breast conserving surgery for invasive breast cancer and DCIS.

Skandarajah AR, Bruce Mann G.

Surgeon. 2013 Oct;11(5):278-85. doi: 10.1016/j.surge.2013.03.005. Epub 2013 Apr 28. Review.

PMID:
23632044
10.

Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score.

Knopfelmacher A, Fox J, Lo Y, Shapiro N, Fineberg S.

Mod Pathol. 2015 Sep;28(9):1167-73. doi: 10.1038/modpathol.2015.79. Epub 2015 Jun 26.

11.

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.

Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang MC, Robertson SJ, Slodkowska E, Fong C, Anderson JM, Jamshidian F, Miller DP, Cherbavaz DB, Shak S, Paszat L.

Breast Cancer Res Treat. 2015 Jul;152(2):389-98. doi: 10.1007/s10549-015-3464-6. Epub 2015 Jun 29.

12.

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD.

Lancet Oncol. 2011 Jan;12(1):21-9. doi: 10.1016/S1470-2045(10)70266-7. Epub 2010 Dec 7.

13.

Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.

Punglia RS, Jiang W, Lipsitz SR, Hughes ME, Schnitt SJ, Hassett MJ, Nekhlyudov L, Achacoso N, Edge S, Javid SH, Niland JC, Theriault RL, Wong YN, Habel LA.

Breast Cancer Res Treat. 2018 Feb;167(3):751-759. doi: 10.1007/s10549-017-4553-5. Epub 2017 Oct 28.

PMID:
29079937
14.

A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.

Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S.

J Natl Cancer Inst. 2013 May 15;105(10):701-10. doi: 10.1093/jnci/djt067. Epub 2013 May 2.

15.

Diagnosis and management of ductal carcinoma in situ (DCIS).

Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ.

Evid Rep Technol Assess (Full Rep). 2009 Sep;(185):1-549. Review.

16.
17.

Post-operative radiotherapy for ductal carcinoma in situ of the breast.

Goodwin A, Parker S, Ghersi D, Wilcken N.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD000563. doi: 10.1002/14651858.CD000563.pub4. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD000563.

PMID:
19160183
18.

Radiotherapy for ductal carcinoma in situ.

Adlard JW, Bundredt NJ.

Clin Oncol (R Coll Radiol). 2006 Apr;18(3):179-84. Review.

PMID:
16605048
20.

Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.

Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R, Taylor C, Tuck A, Sengupta S, Elavathil L, Jani PA, Done SJ, Miller N, Youngson B, Kong I, Paszat L.

Breast Cancer Res Treat. 2013 Apr;138(2):581-90. doi: 10.1007/s10549-013-2455-8. Epub 2013 Mar 3.

PMID:
23456231

Supplemental Content

Support Center